{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:51:54Z","timestamp":1790247114263,"version":"4.1.0"},"reference-count":36,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1210\/jc.2018-01524","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T14:03:08Z","timestamp":1539957788000},"page":"915-924","source":"Crossref","is-referenced-by-count":49,"title":["Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-467X","authenticated-orcid":false,"given":"Ammar","family":"Muhammad","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C","family":"Coopmans","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Internal Medicine and Medical Specialties, Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne E","family":"Franck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-6408","authenticated-orcid":false,"given":"Joseph A M J L","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart Jan","family":"van der Lely","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian J C M M","family":"Neggers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"issue":"24","key":"key\n\t\t\t\t2019020607594332400_B1","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: Acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020607594332400_B2","first-page":"89","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume-title":"Eur J Endocrinol","author":"Holdaway","year":"2008"},{"key":"key\n\t\t\t\t2019020607594332400_B3","first-page":"65","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume-title":"Eur J Endocrinol","author":"Taboada","year":"2007"},{"issue":"4","key":"key\n\t\t\t\t2019020607594332400_B4","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas","volume":"93","author":"Pl\u00f6ckinger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key\n\t\t\t\t2019020607594332400_B5","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key\n\t\t\t\t2019020607594332400_B6","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key\n\t\t\t\t2019020607594332400_B7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key\n\t\t\t\t2019020607594332400_B8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000448429","article-title":"Somatostatin receptor expression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"1","key":"key\n\t\t\t\t2019020607594332400_B9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clpt.2005.04.003","article-title":"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly","volume":"78","author":"Ma","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"key\n\t\t\t\t2019020607594332400_B10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t2019020607594332400_B11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1210\/me.2009-0315","article-title":"Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation","volume":"24","author":"P\u00f6ll","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"3","key":"key\n\t\t\t\t2019020607594332400_B12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key\n\t\t\t\t2019020607594332400_B13","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t2019020607594332400_B14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key\n\t\t\t\t2019020607594332400_B15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tem.2013.11.003","article-title":"Somatostatin analogs: does pharmacology impact antitumor efficacy","volume":"25","author":"Chalabi","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t2019020607594332400_B16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key\n\t\t\t\t2019020607594332400_B17","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019020607594332400_B18","first-page":"654","article-title":"Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3)","volume-title":"Clin Chem Lab Med","author":"Elmlinger","year":"2004"},{"issue":"3","key":"key\n\t\t\t\t2019020607594332400_B19","first-page":"138","article-title":"[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"key":"key\n\t\t\t\t2019020607594332400_B20","author":"Muhammad"},{"issue":"4","key":"key\n\t\t\t\t2019020607594332400_B21","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t2019020607594332400_B22","first-page":"781","article-title":"Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes","volume":"85","author":"Jaquet","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key\n\t\t\t\t2019020607594332400_B23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ib\u00e1\u00f1ez-Costa","year":"2016","journal-title":"J Endocrinol"},{"key":"key\n\t\t\t\t2019020607594332400_B24","first-page":"241","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume-title":"Eur J Endocrinol","author":"Iacovazzo","year":"2016"},{"issue":"11","key":"key\n\t\t\t\t2019020607594332400_B25","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod Pathol"},{"key":"key\n\t\t\t\t2019020607594332400_B26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.humpath.2017.11.008","article-title":"High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs","volume":"72","author":"Kasajima","year":"2018","journal-title":"Hum Pathol"},{"issue":"1","key":"key\n\t\t\t\t2019020607594332400_B27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/cen.12239","article-title":"Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly","volume":"80","author":"Madsen","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key\n\t\t\t\t2019020607594332400_B28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis","volume":"114","author":"Murray","year":"2004","journal-title":"J Clin Invest"},{"issue":"12","key":"key\n\t\t\t\t2019020607594332400_B29","doi-asserted-by":"crossref","first-page":"E1880","DOI":"10.1210\/jc.2013-1987","article-title":"Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists","volume":"98","author":"van der Pas","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"key\n\t\t\t\t2019020607594332400_B30","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019020607594332400_B31","first-page":"645","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume-title":"Eur J Endocrinol","author":"Hofland","year":"2005"},{"issue":"11","key":"key\n\t\t\t\t2019020607594332400_B32","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","article-title":"Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy","volume":"94","author":"Ben-Shlomo","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key\n\t\t\t\t2019020607594332400_B33","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1210\/jc.2003-031319","article-title":"The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key\n\t\t\t\t2019020607594332400_B34","first-page":"4712","article-title":"Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation","volume":"85","author":"Leung","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key\n\t\t\t\t2019020607594332400_B35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1210\/me.2009-0321","article-title":"Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways","volume":"24","author":"Cescato","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"6","key":"key\n\t\t\t\t2019020607594332400_B36","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/me.2010-0398","article-title":"Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists","volume":"25","author":"Kao","year":"2011","journal-title":"Mol Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/3\/915\/27716001\/jc.2018-01524.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T08:01:18Z","timestamp":1549440078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/3\/915\/5136073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,10,19]]},"published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-01524","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,10,19]]}}}